Kanada - angličtina - Health Canada

pfizer canada ulc - dalteparin sodium - solution - 10000unit - dalteparin sodium 10000unit - heparins

Kanada - angličtina - Health Canada

pfizer canada ulc - dalteparin sodium - solution - 12500unit - dalteparin sodium 12500unit - heparins

Kanada - angličtina - Health Canada

pfizer canada ulc - dalteparin sodium - solution - 15000unit - dalteparin sodium 15000unit - heparins

Kanada - angličtina - Health Canada

pfizer canada ulc - dalteparin sodium - solution - 18000unit - dalteparin sodium 18000unit - heparins

Kanada - angličtina - Health Canada

pfizer canada ulc - dalteparin sodium - solution - 2500unit - dalteparin sodium 2500unit - heparins

Kanada - angličtina - Health Canada

pfizer canada ulc - dalteparin sodium - solution - 3500unit - dalteparin sodium 3500unit - heparins

Kanada - angličtina - Health Canada

pfizer canada ulc - dalteparin sodium - solution - 16500unit - dalteparin sodium 16500unit - heparins

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery.,arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.,arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe).,arixtra is indicated for the treatment of unstable angina or non-st segment elevation myocardial infarction (ua/nstemi) for whom urgent (<120 min) invasive management (pci) is not indicated.,arixtra is indicated for the treatment of st segment elevation myocardial infarction (stemi) in patients who are managed without any form of initial reperfusion therapy.

Spojené štáty - angličtina - NLM (National Library of Medicine)

mylan institutional llc - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml - arixtra® is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): arixtra is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. arixtra is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. arixtra is contraindicated in the following conditions: available data from published literature and postmarketing reports have not reported a clear association with fondaparinux sodium and adverse developmental outcomes. fondaparinux sodium plasma concentrations obtained from four women treated with arixtra during pregnancy and their newborn infants demonstrated low placental transfer of fondaparinux sodium (see data). there are risks to the mother associated with untreated venous thromboembolism in pregnancy and a risk of hemorrhage in the mother and fetus associated with use of anticoagulants (see

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium -